J&J Deal With Metabolex Brings Late-Stage Diabetes Candidate To Pipeline
This article was originally published in The Pink Sheet Daily
J&J will pay Metabolex $40 mil. for rights to the Phase II/III insulin sensitizer metaglidasen and other investigational drugs.
You may also be interested in...
A late-stage deal for a type 1 treatment and an early-stage deal for a series of type 2 compounds help J&J's move into diabetes, where it has traditionally been strong in blood glucose monitoring.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.